{"id":"NCT03199053","sponsor":"AstraZeneca","briefTitle":"Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old","officialTitle":"A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial With a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients With Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-11","primaryCompletion":"2023-02-01","completion":"2024-01-03","firstPosted":"2017-06-26","resultsPosted":"2024-04-17","lastUpdate":"2024-06-21"},"enrollment":256,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":["Forxiga"]},{"type":"DRUG","name":"Saxagliptin","otherNames":["Onglyza"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Low dose Dapagliflozin","type":"EXPERIMENTAL"},{"label":"Low dose/high dose Dapagliflozin","type":"EXPERIMENTAL"},{"label":"Low dose Saxagliptin","type":"EXPERIMENTAL"},{"label":"Low dose/high dose Saxagliptin","type":"EXPERIMENTAL"},{"label":"Placebo arm","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to determine if there will be a greater mean reduction from baseline in glycated hemoglobin (HbA1c) achieved after 26 weeks of oral double-blind add-on therapy of dapagliflozin or saxagliptin compared to placebo in paediatric T2DM patients with HbA1c levels of 6.5 to 10.5% on diet and exercise and metformin, insulin, or metformin plus insulin.","primaryOutcome":{"measure":"Dapagliflozin Versus Placebo: Adjusted Mean Change From Baseline in HbA1c at Week 26","timeFrame":"Baseline and Week 26","effectByArm":[{"arm":"Dapagliflozin","deltaMin":-0.62,"sd":0.218},{"arm":"Placebo","deltaMin":0.41,"sd":0.218}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"}]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":28},"locations":{"siteCount":122,"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","Colombia","Finland","India","Israel","Italy","Malaysia","Mexico","New Zealand","Philippines","Poland","Russia","South Korea","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["38320500"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D1680C00019&amp;attachmentIdentifier=9f610176-081e-4659-a955-31192c46471e&amp;fileName=CSR_Synopsis_Redacted_pdfa.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D1680C00019&amp;attachmentIdentifier=a8045694-354d-4408-bff7-6fee81e69119&amp;fileName=SAP_Redacted_pdfa.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D1680C00019&amp;attachmentIdentifier=ffb4f464-404c-4c9e-8a5d-1366c1c38e5a&amp;fileName=CSP_Redacted_pdfa.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":81},"commonTop":["Headache","Urinary tract infection","Vitamin d deficiency","Influenza","Nasopharyngitis"]}}